J A Mancini

Summary

Affiliation: Merck Research Laboratories
Country: USA

Publications

  1. ncbi request reprint Altered sensitivity of aspirin-acetylated prostaglandin G/H synthase-2 to inhibition by nonsteroidal anti-inflammatory drugs
    J A Mancini
    Department of Biochemistry and Molecular Biology, Merck Frosst Centre for Therapeutic Research, Kirkland, Quebec, Canada
    Mol Pharmacol 51:52-60. 1997
  2. pmc Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor
    D Riendeau
    Merck Frosst Centre for Therapeutic Research, Kirkland, Quebec, Canada
    Br J Pharmacol 121:105-17. 1997
  3. ncbi request reprint Correlation between expression of 5-lipoxygenase-activating protein, 5-lipoxygenase, and cellular leukotriene synthesis
    G K Reid
    Department of Pharmacology, Merck Frosst Centre for Therapeutic Research, Pointe Claire Dorval, Quebec, Canada
    J Biol Chem 265:19818-23. 1990
  4. ncbi request reprint 5-lipoxygenase-activating protein is an arachidonate binding protein
    J A Mancini
    Department of Pharmacology, Merck Frosst Centre for Therapeutic Research, Quebec, Canada
    FEBS Lett 318:277-81. 1993
  5. ncbi request reprint Identification and characterization of a novel human microsomal glutathione S-transferase with leukotriene C4 synthase activity and significant sequence identity to 5-lipoxygenase-activating protein and leukotriene C4 synthase
    P J Jakobsson
    Merck Frosst Centre for Therapeutic Research, Kirkland, Quebec, Canada H9H 3L1
    J Biol Chem 271:22203-10. 1996
  6. ncbi request reprint Identification and characterization of a novel microsomal enzyme with glutathione-dependent transferase and peroxidase activities
    P J Jakobsson
    Merck Frosst Centre for Therapeutic Research, Pointe Claire Dorval, Quebec H9R 4P8, Canada
    J Biol Chem 272:22934-9. 1997
  7. ncbi request reprint 5-Lipoxygenase-activating protein is the target of a quinoline class of leukotriene synthesis inhibitors
    J F Evans
    Department of Pharmacology, Merck Frosst Centre for Therapeutic Research, Quebec, Canada
    Mol Pharmacol 40:22-7. 1991
  8. ncbi request reprint Characterization of microsomal GST-II by western blot and identification of a novel LTC4 isomer
    P J Jakobsson
    Merck Frosst Centre for Therapeutic Research, Kirkland, Quebec, Canada
    J Lipid Mediat Cell Signal 17:15-9. 1997
  9. ncbi request reprint Cloning and expression of rhesus monkey cathepsin K
    J Guay
    Department of Biochemistry and Molecular Biology, Merck Frosst Centre for Therapeutic Research, Kirkland, Quebec, Canada
    Bone 25:205-9. 1999
  10. ncbi request reprint Cloning, expression, and up-regulation of inducible rat prostaglandin e synthase during lipopolysaccharide-induced pyresis and adjuvant-induced arthritis
    J A Mancini
    Departments of Biochemistry and Molecular Biology and Pharmacology, Merck Frosst Centre for Therapeutic Research, Kirkland, Quebec H9R 4P8, Canada
    J Biol Chem 276:4469-75. 2001

Collaborators

Detail Information

Publications19

  1. ncbi request reprint Altered sensitivity of aspirin-acetylated prostaglandin G/H synthase-2 to inhibition by nonsteroidal anti-inflammatory drugs
    J A Mancini
    Department of Biochemistry and Molecular Biology, Merck Frosst Centre for Therapeutic Research, Kirkland, Quebec, Canada
    Mol Pharmacol 51:52-60. 1997
    ....
  2. pmc Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor
    D Riendeau
    Merck Frosst Centre for Therapeutic Research, Kirkland, Quebec, Canada
    Br J Pharmacol 121:105-17. 1997
    ....
  3. ncbi request reprint Correlation between expression of 5-lipoxygenase-activating protein, 5-lipoxygenase, and cellular leukotriene synthesis
    G K Reid
    Department of Pharmacology, Merck Frosst Centre for Therapeutic Research, Pointe Claire Dorval, Quebec, Canada
    J Biol Chem 265:19818-23. 1990
    ..Cellular leukotriene synthesis in this system is functionally dependent on FLAP as shown by its inhibition by the leukotriene biosynthesis inhibitor MK-886, a compound which specifically binds to FLAP...
  4. ncbi request reprint 5-lipoxygenase-activating protein is an arachidonate binding protein
    J A Mancini
    Department of Pharmacology, Merck Frosst Centre for Therapeutic Research, Quebec, Canada
    FEBS Lett 318:277-81. 1993
    ..These studies suggest that FLAP may activate 5-LO by specifically binding arachidonic acid and transferring this substrate to the enzyme...
  5. ncbi request reprint Identification and characterization of a novel human microsomal glutathione S-transferase with leukotriene C4 synthase activity and significant sequence identity to 5-lipoxygenase-activating protein and leukotriene C4 synthase
    P J Jakobsson
    Merck Frosst Centre for Therapeutic Research, Kirkland, Quebec, Canada H9H 3L1
    J Biol Chem 271:22203-10. 1996
    ..Therefore, it is proposed that this novel membrane protein is a member of the microsomal glutathione S-transferase family, also including LTC4 synthase, with significant sequence identities to both LTC4 synthase and FLAP...
  6. ncbi request reprint Identification and characterization of a novel microsomal enzyme with glutathione-dependent transferase and peroxidase activities
    P J Jakobsson
    Merck Frosst Centre for Therapeutic Research, Pointe Claire Dorval, Quebec H9R 4P8, Canada
    J Biol Chem 272:22934-9. 1997
    ..Based on these catalytic activities it is proposed that this novel membrane protein is a member of the microsomal glutathione S-transferase super family, which also includes microsomal GST-I, LTC4 synthase, FLAP, and microsomal GST-II...
  7. ncbi request reprint 5-Lipoxygenase-activating protein is the target of a quinoline class of leukotriene synthesis inhibitors
    J F Evans
    Department of Pharmacology, Merck Frosst Centre for Therapeutic Research, Quebec, Canada
    Mol Pharmacol 40:22-7. 1991
    ..These results suggest a direct binding site for the quinoline leukotriene synthesis inhibitors on FLAP and provide further evidence for the essential role of FLAP in cellular leukotriene synthesis...
  8. ncbi request reprint Characterization of microsomal GST-II by western blot and identification of a novel LTC4 isomer
    P J Jakobsson
    Merck Frosst Centre for Therapeutic Research, Kirkland, Quebec, Canada
    J Lipid Mediat Cell Signal 17:15-9. 1997
    ..In addition to catalyzing the biosynthesis of LTC4, microsomal GST-II also produces another product, which has been subjected to mass spectrometric analysis. This analysis demonstrates that the novel product is an isomer of LTC4...
  9. ncbi request reprint Cloning and expression of rhesus monkey cathepsin K
    J Guay
    Department of Biochemistry and Molecular Biology, Merck Frosst Centre for Therapeutic Research, Kirkland, Quebec, Canada
    Bone 25:205-9. 1999
    ....
  10. ncbi request reprint Cloning, expression, and up-regulation of inducible rat prostaglandin e synthase during lipopolysaccharide-induced pyresis and adjuvant-induced arthritis
    J A Mancini
    Departments of Biochemistry and Molecular Biology and Pharmacology, Merck Frosst Centre for Therapeutic Research, Kirkland, Quebec H9R 4P8, Canada
    J Biol Chem 276:4469-75. 2001
    ..The results demonstrate that PGE synthase is up-regulated in vivo after LPS or adjuvant administration and suggest that this is a key enzyme involved in the formation of PGE(2) in COX-2-mediated inflammatory and pyretic responses...
  11. ncbi request reprint Cellular oxygenation of 12-hydroxyeicosatetraenoic acid and 15-hydroxyeicosatetraenoic acid by 5-lipoxygenase is stimulated by 5-lipoxygenase-activating protein
    J A Mancini
    Department of Biochemistry and Molecular Biology, Merck Frosst Centre for Therapeutic Research, Kirkland, Quebec H9R 4P8, Canada
    J Biol Chem 273:32842-7. 1998
    ....
  12. ncbi request reprint L-454,560, a potent and selective PDE4 inhibitor with in vivo efficacy in animal models of asthma and cognition
    Z Huang
    Department of Biochemistry and Molecular Biology, Merck Frosst Centre for Therapeutic Research, Kirkland, Quebec, Canada
    Biochem Pharmacol 73:1971-81. 2007
    ..Therefore, L-454,560 is a novel PDE4 inhibitor with an overall in vivo efficacy profile at least comparable to roflumilast and clearly superior to cilomilast...
  13. ncbi request reprint 5-Lipoxygenase activity in the human pancreas
    J A Mancini
    Department of Pharmacology, Merck Frosst Centre for Therapeutic Research, Quebec, Canada
    J Lipid Mediat 8:145-50. 1993
    ..Western blot analysis demonstrated that the human pancreas contains low levels of 5-lipoxygenase-activating protein (FLAP) in addition to 5-LO...
  14. ncbi request reprint Characterization of a 5-lipoxygenase-activating protein binding assay: correlation of affinity for 5-lipoxygenase-activating protein with leukotriene synthesis inhibition
    S Charleson
    Department of Pharmacology, Merck Frosst Centre for Therapeutic Research, Quebec, Canada
    Mol Pharmacol 41:873-9. 1992
    ..In addition, direct 5-lipoxygenase inhibitors and a selection of eicosanoids were unable to compete for FLAP binding. This study validates a selective binding assay for leukotriene synthesis inhibitors whose protein target is FLAP...
  15. ncbi request reprint Cloning and characterization of the human leukotriene A4 hydrolase gene
    J A Mancini
    Department of Biochemistry and Molecular Biology, Merck Frosst Canada Inc, Pointe Claire Dorval, Quebec, Canada
    Eur J Biochem 231:65-71. 1995
    ..The cloning and characterization of the human gene for LTA4 hydrolase provides a basis for further insight into transcriptional regulation of this bifunctional enzyme and its role in various inflammatory processes...
  16. ncbi request reprint Preferential inhibition of T helper 1, but not T helper 2, cytokines in vitro by L-826,141 [4-[2-(3,4-Bisdifluromethoxyphenyl)-2-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)-phenyl]-ethyl]3-methylpyridine-1-oxide], a potent and selective phosphodieste
    D Claveau
    Department of Biochemistry and Molecular Biology, Merck Frosst Centre for Therapeutic Research, P O Box 1005, Pointe Claire Dorval, Quebec, Canada H9R 4P8
    J Pharmacol Exp Ther 310:752-60. 2004
    ..5 microM) on Th2 cell-mediated IL-4 nor IL-13 production. Together, these data demonstrate that specific inhibition of PDE4 preferentially blocks the production of Th1 versus Th2 effector cytokines in vitro...
  17. ncbi request reprint Cross-species comparison of 5-lipoxygenase-activating protein
    P J Vickers
    Department of Pharmacology, Merck Frosst Centre for Therapeutic Research, Pointe Claire Dorval, Quebec, Canada
    Mol Pharmacol 42:1014-9. 1992
    ..Two regions of the protein are almost totally conserved among all of the species analyzed. This suggests that these regions have functional significance and may be involved in inhibitor binding...
  18. ncbi request reprint Urogenital distribution of a mouse membrane-associated prostaglandin E(2) synthase
    Y Guan
    Division of Nephrology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee 37212, USA
    Am J Physiol Renal Physiol 281:F1173-7. 2001
    ..In conclusion, mPGES is constitutively expressed along the urogenital tract, where it may have important roles in normal physiology and disease...
  19. ncbi request reprint Peripheral phosphodiesterase 4 inhibition produced by 4-[2-(3,4-Bis-difluoromethoxyphenyl)-2-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)-phenyl]-ethyl]-3-methylpyridine-1-oxide (L-826,141) prevents experimental autoimmune encephalomyelitis
    C S Moore
    Department of Pharmacology, Faculty of Medicine, Sir Charles Tupper Bldg, 5850 College St, Halifax, NS B3H 1X5, Canada
    J Pharmacol Exp Ther 319:63-72. 2006
    ....